Drug Delivery and Translational Research

, Volume 5, Issue 2, pp 116–124 | Cite as

Evans blue nanocarriers visually demarcate margins of invasive gliomas

  • Benjamin T. Roller
  • Jennifer M. Munson
  • Barunashish Brahma
  • Philip J. Santangelo
  • S. Balakrishna Pai
  • Ravi V. Bellamkonda
Research Article

Abstract

Aggressive surgical resection is the primary therapy for glioma. However, aggressive resection may compromise functional healthy brain tissue. Currently, there are no objective cues for surgeons to distinguish healthy tissue from tumor and determine tumor borders; surgeons skillfully rely on subjective means such as tactile feedback. This often results in incomplete resection and recurrence. The objective of the present study was to design, develop, and evaluate, in vitro and in vivo, a nanoencapsulated visible dye for intraoperative, visual delineation of tumor margins in an invasive tumor model. Liposomal nanocarriers containing Evans blue dye (nano-EB) were developed, characterized, and tested for safety in vitro and in vivo. 3RT1RT2A glioma cells were implanted into brains of Fischer 344 rats. Nano-EB or EB solution was injected via tail vein into tumor-bearing animals. To assess tumor staining, tissue samples were analyzed visibly and using fluorescence microscopy. Area, perimeter ratios, and Manders overlap coefficients were calculated to quantify extent of staining. Nano-EB clearly marked tumor margins in the invasive tumor model. Area ratio of nano-EB staining to tumor was 0.89 ± 0.05, perimeter ratio was 0.94 ± 0.04, Manders R was 0.51 ± 0.08, and M1 was 0.97 ± 0.06. Microscopic tumor border inspection under high magnification verified that nano-EB did not stain healthy tissue. Nano-EB clearly aids in distinguishing tumor tissue from healthy tissue in an invasive tumor model, while injection of unencapsulated EB results in false identification of healthy tissue as tumor due to diffusion of dye from the tumor into healthy tissue.

Keywords

Nanocarriers Liposomes Tumor margin Tumor border Intraoperative MRI Tumor resection 

References

  1. 1.
    Guthrie BL, Laws Jr ER. Supratentorial low-grade gliomas. Neurosurg Clin N Am. 1990;1:37–48.PubMedGoogle Scholar
  2. 2.
    Black P. Management of malignant glioma: role of surgery in relation to multimodality therapy. J Neurovirol. 1998;4:227–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999;52:371–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Yasargil MG, Kadri PA, Yasargil DC. Microsurgery for malignant gliomas. J Neurooncol. 2004;69:67–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010;67:279–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753–64. discussion 264–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Choucair AK, Levin VA, Gutin PH, Davis RL, Silver P, Edwards MS, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg. 1986;65:654–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Mornex F, Nayel H, Taillandier L. Radiation therapy for malignant astrocytomas in adults. Radiother Oncol. 1993;27:181–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Britz GW, Ghatan S, Spence AM, Berger MS. Intracarotid RMP-7 enhanced indocyanine green staining of tumors in a rat glioma model. J Neurooncol. 2002;56:227–32.CrossRefPubMedGoogle Scholar
  10. 10.
    Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003;63:8122–5.PubMedGoogle Scholar
  11. 11.
    Pham W, Medarova Z, Moore A. Synthesis and application of a water-soluble near-infrared dye for cancer detection using optical imaging. Bioconjug Chem. 2005;16:735–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, et al. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 2007;67:6882–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A. 2010;107:4317–22.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ozawa T, Britz GW, Kinder DH, Spence AM, VandenBerg S, Lamborn KR, et al. Bromophenol blue staining of tumors in a rat glioma model. Neurosurgery. 2005;57:1041–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Orringer DA, Chen T, Huang DL, Armstead WM, Hoff BA, Koo YE, et al. The brain tumor window model: a combined cranial window and implanted glioma model for evaluating intraoperative contrast agents. Neurosurgery. 2010;66:736–43.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Stojiljkovic M, Piperski V, Dacevic M, Rakic L, Ruzdijic S, Kanazir S. Characterization of 9 L glioma model of the Wistar rat. J Neurooncol. 2003;63:1–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Karathanasis E, Chan L, Karumbaiah L, McNeeley K, D’Orsi CJ, Annapragada AV, et al. Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers. PLoS One. 2009;4:e5843.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Popovic Z, Liu W, Chauhan VP, Lee J, Wong C, Greytak AB, et al. A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl. 2010;49:8649–52.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg. 1995;83:1029–37.CrossRefPubMedGoogle Scholar
  20. 20.
    Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000;11:1029–33.CrossRefPubMedGoogle Scholar
  21. 21.
    O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–9.CrossRefPubMedGoogle Scholar
  22. 22.
    McNeeley K, Annapragada A, Bellamkonda R. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology. 2007;18:385101–11.CrossRefGoogle Scholar
  23. 23.
    International Telecommunications Union R. Rec. BT. Encoding parameters of digital television for studios. 1994; 601–4.Google Scholar
  24. 24.
    Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497–509.PubMedGoogle Scholar
  25. 25.
    Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW, Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys. 1996;36:1177–87.CrossRefPubMedGoogle Scholar
  26. 26.
    Karumbaiah L, Anand S, Thazhath R, Zhong Y, McKeon RJ, Bellamkonda RV. Targeted downregulation of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase significantly mitigates chondroitin sulfate proteoglycan-mediated inhibition. Glia. 2011;59:981–96.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Fillmore HL, Shurm J, Furqueron P, Prabhu SS, Gillies GT, Broaddus WC. An in vivo rat model for visualizing glioma tumor cell invasion using stable persistent expression of the green fluorescent protein. Cancer Lett. 1999;141:9–19.CrossRefPubMedGoogle Scholar
  28. 28.
    Manders E, Verbeek F, Aten I. Measurement of co-localization of objects in dual-colour confocal images. J Microsc. 1993;169:375–82.CrossRefGoogle Scholar
  29. 29.
    Hueper WC, Ichniowski C. Toxicopathologic studies on the dye T-1824. AMA Arch Surg. 1944;48:17.CrossRefGoogle Scholar
  30. 30.
    Roberts LN. Evans blue toxicity. Can Med Assoc J. 1954;71:489–91.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Zinchuk V, Zinchuk O. Quantitative colocalization analysis of confocal fluorescence microscopy images. Curr Protoc Cell Biol. 2008; Chapter 4: Unit 4.19.Google Scholar
  32. 32.
    Raore B, Schniederjan M, Prabhu R, Brat DJ, Shu HK, Olson JJ. Metastasis Infiltration: an investigation of the postoperative brain–tumor interface. Int J Radiat Oncol Biol Phys. 2010; 1–6.Google Scholar
  33. 33.
    Sadzuka Y, Hirama R, Sonobe T. Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy. Toxicol Lett. 2002;126:83–90.CrossRefPubMedGoogle Scholar
  34. 34.
    Pradhan P, Giri J, Rieken F, Koch C, Mykhaylyk O, Doblinger M, et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release. 2009;142:108–21.CrossRefPubMedGoogle Scholar
  35. 35.
    Agarwal A, Mackey MA, El-Sayed MA, Bellamkonda RV. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. ACS Nano. 2011;5:4919–26.CrossRefPubMedGoogle Scholar
  36. 36.
    Lindner V, Heinle H. Binding properties of circulating Evans blue in rabbits as determined by disc electrophoresis. Atherosclerosis. 1982;43:417–22.CrossRefPubMedGoogle Scholar

Copyright information

© Controlled Release Society 2013

Authors and Affiliations

  • Benjamin T. Roller
    • 1
  • Jennifer M. Munson
    • 1
  • Barunashish Brahma
    • 2
    • 3
  • Philip J. Santangelo
    • 1
  • S. Balakrishna Pai
    • 1
  • Ravi V. Bellamkonda
    • 1
    • 4
  1. 1.Wallace H Coulter Department of Biomedical EngineeringGeorgia Institute of Technology and Emory School of MedicineAtlantaUSA
  2. 2.Department of NeurosurgeryChildren’s Healthcare of Atlanta, and Emory University School of MedicineAtlantaUSA
  3. 3.Department of NeurosurgeryEmory University School of MedicineAtlantaUSA
  4. 4.Wallace H Coulter Department of Biomedical EngineeringGeorgia Institute of Technology and Emory School of MedicineAtlantaUSA

Personalised recommendations